Bevaris Injection 100 mg/4 ml contains Bevacizumab, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is an anti-angiogenic targeted therapy used in combination with chemotherapy or other anticancer treatments for the management of several advanced, recurrent, and metastatic cancers. By blocking the formation of new blood vessels that nourish tumors, Bevacizumab helps slow cancer growth and disease progression.

Tumors depend on the development of new blood vessels to receive oxygen and nutrients necessary for growth. Bevacizumab binds specifically to VEGF, preventing it from activating VEGF receptors on blood vessel cells. This inhibits angiogenesis, reducing the blood supply to tumors and limiting their ability to grow and spread to other parts of the body.

Bevaris Injection is administered as an intravenous (IV) infusion under the supervision of an experienced oncologist or qualified healthcare professional. It is widely used as part of combination therapy for several types of solid tumors and has become an important component of modern targeted cancer treatment. The 100 mg/4 ml presentation offers dosing flexibility, allowing oncologists to individualize treatment based on the patient's body weight, cancer type, and therapeutic regimen.

Because Bevacizumab can affect wound healing and increase the risk of hypertension, bleeding, blood clots, and proteinuria, patients require careful monitoring throughout treatment. Regular clinical assessments and laboratory investigations help ensure the medicine is used safely and effectively.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Bevaris Injection 100 mg/4 ml is indicated for the treatment of:

• Metastatic colorectal cancer
• Non-squamous non-small cell lung cancer (NSCLC)
• Recurrent glioblastoma
• Metastatic renal cell carcinoma
• Persistent, recurrent, or metastatic cervical cancer
• Epithelial ovarian, fallopian tube, and primary peritoneal cancer
• Other approved oncology indications as determined by an oncologist

How Bevaris Injection Works

Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF). By blocking VEGF, it prevents the formation of new blood vessels that supply oxygen and nutrients to tumors. This anti-angiogenic action slows tumor growth, limits cancer spread, and enhances the effectiveness of other anticancer therapies.

Benefits of Bevaris Injection

• Inhibits the formation of blood vessels that feed tumors.
• Slows the growth and progression of various cancers.
• Enhances the effectiveness of chemotherapy in selected cancers.
• Helps prolong progression-free survival in appropriate patients.
• Provides targeted anti-VEGF therapy.
• Offers flexible dosing based on individual treatment requirements.
• Administered under specialist supervision for optimal cancer management.

Dosage and Administration

Bevaris Injection should be administered only by qualified healthcare professionals experienced in oncology.

• Administered by intravenous infusion.
• The dosage is calculated according to body weight, cancer type, and treatment protocol.
• It may be used alone or in combination with chemotherapy or other targeted therapies.
• Patients should be monitored during and after infusion for infusion-related reactions and other adverse effects.

The duration of treatment depends on the patient's clinical response, tolerance, and the oncologist's recommendations.

Possible Side Effects

Like all medicines, Bevaris Injection may cause side effects, although not everyone experiences them.

Common side effects include:

• High blood pressure
• Fatigue
• Headache
• Nosebleeds
• Protein in the urine
• Diarrhea
• Loss of appetite

Serious side effects may include:

• Gastrointestinal perforation
• Severe bleeding
• Blood clots
• Delayed wound healing
• Heart failure
• Kidney problems
• Infusion-related reactions
• Severe allergic reactions

Seek immediate medical attention if you experience severe abdominal pain, chest pain, sudden shortness of breath, heavy bleeding, severe headache, or signs of a serious allergic reaction.

Precautions and Warnings

Before receiving Bevaris Injection, inform your healthcare provider if you have:

• High blood pressure
• Heart disease
• Kidney disease
• Bleeding disorders
• Recent or planned surgery
• History of blood clots or stroke
• Pregnancy or plans to become pregnant
• Breastfeeding

Bevacizumab may impair wound healing. Treatment is generally withheld before and after major surgery according to your physician's recommendations.

Regular monitoring of blood pressure, urine protein, kidney function, and overall clinical status is recommended during treatment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

Store refrigerated at 2°C to 8°C. Do not freeze or shake the vial. Keep the vial in its original carton to protect it from light. Keep out of the reach of children.

Disclaimer

Bevaris Injection 100 mg/4 ml is a prescription anticancer medicine and should only be administered under the supervision of qualified oncology specialists. Careful monitoring during treatment is essential to ensure safe and effective therapy. Always follow your oncologist's recommendations regarding dosage and treatment schedule.